ScholarLens Back to search
2013•American Journal of Hospice and Palliative Medicine®Requires access

Use of Methylphenidate for the Management of Fatigue in Chinese Patients With Cancer

Steven Wai Kwan Siu, Martin Law, Rico K.Y. Liu, Kam-Hung Wong, Inda Soong, Annie O. L. Kwok, K. H. Ng, Po Tin Lam, Thomas Leung

Open publisher page 5 citations

Abstract

UNLABELLED: REASON FOR THE STUDY: Studies on methylphenidate for cancer-related fatigue showed conflicting results. This prospective study aims to determine whether methylphenidate is useful for relieving fatigue in Chinese patients with cancer. Chinese Version of Brief Fatigue Inventory (BFI-C) was administered on days 1, 8, and 29. Methylphenidate dose on day 1 was 5 mg daily then adjusted after day 8 according to response and side effects tolerance. MAIN FINDINGS: Only 48% of the 25 recruited patients were on methylphenidate by day 29. Overall, no significant improvement in fatigue level was observed after methylphenidate, though benefits were shown in subgroups with age ≤ 65 and higher baseline BFI-C values. PRINCIPAL CONCLUSIONS: Methylphenidate may be useful for management of cancer-related fatigue in selected Chinese patients.

About this research paper

What this paper is about

UNLABELLED: REASON FOR THE STUDY: Studies on methylphenidate for cancer-related fatigue showed conflicting results. This prospective study aims to determine whether methylphenidate is useful for relieving fatigue in Chinese patients with cancer. Chinese Version of Brief Fatigue Inventory (BFI-C) was administered on days 1, 8, and 29. Methylphenidate dose on day 1 was 5 mg daily then adjusted after day 8 according to response and side effects tolerance. MAIN FINDINGS: Only 48% of the 25 recruited patients were on methylphenidate by day 29. Overall, no significant improvement in fatigue level was observed after methylphenidate, though benefits were shown in subgroups with age ≤ 65 and higher baseline BFI-C values. PRINCIPAL CONCLUSIONS: Methylphenidate may be useful for management of cancer-related fatigue in selected Chinese patients.

Why it matters

OpenAlex reports 5 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

UNLABELLED: REASON FOR THE STUDY: Studies on methylphenidate for cancer-related fatigue showed conflicting results. This prospective study aims to determine whether methylphenidate is useful for relieving fatigue in Chinese patients with cancer. Chinese Version of Brief Fatigue Inventory (BFI-C) was administered on days 1, 8, and 29. Methylphenidate dose on day 1 was 5 mg daily then adjusted after day 8 according to response and side effects tolerance. MAIN FINDINGS: Only 48% of the 25 recruited patients were on methylphenidate by day 29. Overall, no significant improvement in fatigue level was observed after methylphenidate, though benefits were shown in subgroups with age ≤ 65 and higher baseline BFI-C values. PRINCIPAL CONCLUSIONS: Methylphenidate may be useful for management of cancer-related fatigue in selected Chinese patients.

Key concepts: Methylphenidate, Cancer-related fatigue, Medicine, Childhood cancer, Prospective cohort study, Cancer, Psychiatry, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Use of Methylphenidate for the Management of Fatigue in Chinese Patients With Cancer — Research Paper | ScholarLens